

**OFFICIAL CONTROL AUTHORITY
BATCH RELEASE
OF
IMMUNOLOGICAL VETERINARY
MEDICINAL PRODUCTS**

2012

EQUINE INFLUENZA VACCINE (INACTIVATED)

Document title	Official control authority batch release of equine influenza vaccines (inactivated)
Legislative basis	Council Directive 2001/82/EC amended by Directive 2004/28/EC
Date of first adoption	October 2005
Date of original entry into force	October 31, 2005
Status	Editorial update of EDQM website address
Date of entry into force of present version	May 1, 2012
Previous titles/other references	PILOT PHASE (October 2005-October 2006) Formally finalised under PA/PH/OMCL (04) 4 DEF
Custodian Organisation	The present document was elaborated by the EDQM through the OMCL network and is finalised under PA/PH/OMCL (04) 4 DEF CORR

OFFICIAL CONTROL AUTHORITY BATCH RELEASE PROTOCOL FOR EQUINE INFLUENZA VACCINE (INACTIVATED)¹

OMCLs performing batch release on this product should receive a completed signed protocol from the MAH (model template available separately on the EDQM website (www.edqm.eu)) and the required samples.

The licensing authority provides the OMCL with all necessary data from the quality part of the dossier such as relevant Pharmacopoeia monographs, list of tests to be performed on each batch and the SOPs as presented in the dossier.

1 INTRODUCTION

Official Control Authority Batch Release of immunological products for veterinary use is performed within the framework of Article 82 of Directive 2001/82/EC as amended by Directive 2004/28/EC and following the current guideline on EC administrative procedure for official control authority batch release of IVMPs.

The Ph Eur monograph 0249 is relevant for this product.

2 SAMPLING AND TESTS TO BE PERFORMED BY THE OFFICIAL CONTROL LABORATORY

The following samples should be supplied to the Official Medicines Control Laboratory performing batch release:

At least 20 containers of each final lot.

The Control Laboratory should perform the following tests:

- Appearance
- Potency – Potency testing is done on the first batch from a final bulk and then all other batches derived from that same bulk shall not be re-tested.

¹ This guideline does not cover GMO derived vaccines. The question remains whether a guideline for GMO derived Equine Influenza vaccines should be developed to ensure equal treatment of all vaccines for this disease.